AMG 706 / AMG706


    AMG 706 is Amgen's first small molecule anti-cancer therapeutic candidate, which selectively inhibits multiple kinases involved in the formation of blood vessels. AMG 706 appeared to reduce vascular permeability and blood flow in human tumors in a Phase 1 trial. Early clinical data shows signs of tumor regression with promising preliminary safety data that allows for combination therapy. (from

    Phase I trials are underway at John Wayne Cancer Institute (Santa Monica, Ca.) and at M.D. Anderson Cancer Center (Houston, Texas)


Sign up for the AMG 706 / AMG706 chat group on Yahoo




Yahoo Groups Chat Site   : Discussion forum for anyone interested in AMG 706 / AMG706

AMG 706 : Amgen's info page

AMG 706 :  M.D. Anderson Cancer Center's Phase 1 Clinical Trial

AMG 706 : Phase II Clinical Trial - GIST patients

GSI : Gist Support International  (Gastrointestinal Stromal Tumors) - current AMG 706 info is posted here.  

AMG Abstract :  Released by Amgen in October 2004.





     I am not a medical or health professional.  Information in this site has been gathered from numerous sources and is for research purposes only.  I do not guarantee the accuracy of any information in this site.    Desmoplastic Small Round Cell Tumor